This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2012 by AB Science.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
AB Science Identifier:
First received: October 6, 2011
Last updated: September 25, 2012
Last verified: September 2012
The study objective is to compare the efficacy and the safety of masitinib at 6 mg/kg/day versus placebo in the treatment of patients with Severe Persistent Asthma treated with oral corticosteroids.

Condition Intervention Phase
Asthma Drug: masitinib 6 mg/kg/day Drug: placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective, Multicenter, Randomised, Double-blind, Placebo-controlled, 2-parallel Groups, Phase 3 Study to Compare the Efficacy and the Safety of Masitinib at 6 mg/kg/Day Versus Placebo in the Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids

Resource links provided by NLM:

Further study details as provided by AB Science:

Primary Outcome Measures:
  • asthma exacerbation rate [ Time Frame: week 36 ]

Secondary Outcome Measures:
  • asthma control questionnaire score [ Time Frame: week 36 ]
  • moderate and severe asthma exacerbation rate [ Time Frame: week 36 ]

Estimated Enrollment: 300
Study Start Date: June 2011
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: masitinib
masitinib 6 mg/kg/day
Drug: masitinib 6 mg/kg/day
6 mg/kg/day
Placebo Comparator: placebo
placebo matching masitinib 6 mg/kg/day
Drug: placebo
placebo matching masitinib 6 mg/kg/day


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient with severe persistent asthma already treated
  2. Patient with history of asthma > 1 year prior to screening visit
  3. Patient with no significant change in the regular asthma medication, no severe asthma exacerbation for at least 4 weeks prior to screening visit
  4. Non-smoker patient for at least one year and with a prior tobacco consumption < 10 packs a year

Exclusion Criteria:

  1. Asthmatic patient still exposed to allergens or to triggering factors influencing asthma control
  2. Patient with history of acute infectious sinusitis or respiratory tract infection within 4 weeks prior to screening
  3. Patient presenting with cardiac disorders
  4. Patient with active lung disease other than asthma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01449162

Contact: Christophe LEROYER, MD, PhD

University of Debrecen Medical and Health Science Center Recruiting
Debrecen, Hungary, 4032
Sponsors and Collaborators
AB Science
  More Information

Responsible Party: AB Science Identifier: NCT01449162     History of Changes
Other Study ID Numbers: AB07015
Study First Received: October 6, 2011
Last Updated: September 25, 2012

Keywords provided by AB Science:
severe persistent asthma
patients treated with oral corticosteroids

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases processed this record on September 21, 2017